Ginkgo Bioworks Holdings Inc (NYSE:DNA)
$ 9.66 -0.56 (-5.48%) Market Cap: 587.43 Mil Enterprise Value: 367.95 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Q3 2024 Ginkgo Bioworks Holdings Inc Earnings Call Transcript

Nov 12, 2024 / 10:30PM GMT
Release Date Price: $8.39 (-4.22%)
Editor

Portions of this transcript marked (audio in progress) indicate audio problems. The missing text will be supplied if a replay becomes available.

Megan LeDuc
Ginkgo Bioworks Holdings Inc - Manager, Investor Relations

(audio in progress) Shift from small early-stage customers tumors, along with the change made as part of the restructuring, we supported a total of 136 active programs across 81 customers on the cell engineering platform. This represents a 17% increase in active programs each year over year.

As we discussed at our Q1 and Q2 earnings calls, the nature of programs that we take some of ours has evolved following our recent adjustments to commercial terms and the launch of our debt offering while still very early days.

This slide gives you some detail on how the nature of programs is changing. We added a total of 25 new bids and contracts in Q3 2024, of which 11 were generally comparable in size and scope just historically reported new programs and were included in the current active program count on the prior slide.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot